Drug intelligence / Profile preview

REPROGRAHT

Development stage: Unknown
Lead developer: Qurgen
Modality: Recombinant Proteins and Enzymes

Overview

REPROGRAHT is a protein-based regenerative medicine candidate developed by Qurgen for the treatment of heart failure. Currently in Phase 2 clinical development, the therapeutic is designed to promote the repair and regeneration of damaged cardiac tissue. It belongs to a class of regenerative therapies that utilize specific proteins to trigger endogenous healing processes or cellular reprogramming within the heart to restore myocardial function following injury or chronic failure.

Beyond the preview

Go deeper on REPROGRAHT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REPROGRAHT.

Explore the full profile